According to a recently published report, the Global Biopsy Devices Market is expected to grow at the CAGR of 9% during 2015-2022 and it is estimated to be $XX billion by 2022. The global Biopsy devices market is segmented on the basis of products and geography. The report on global Biopsy devices market forecast 2012-2022 provides detailed overview and predictive analysis of the market.
The market is driven by increasing prevalence of cancer. There is constant need for high quality diagnostic and therapeutic processes. However, such unmet patient needs has forced the companies and governments to work in order to provide better services. Population aging is a major influence on patterns of health care spending in both developed and developing countries. In developed countries such as the U.S. and western European countries, where point of care healthcare services and institutional long-term care services and medcare policies are available. The proportion of aged people using healthcare services is high. The per capita health expenditure on healthcare is higher as compared to other age groups. There is constant pressure on the healthcare services as the number of older people increases. Such factors are driving the biopsy market.
Full report available global Biopsy devices market forecast 2012-2022 report at http://briskinsights.com/report/global-biopsy-devices-market-forecast-2012-2022
Biopsy market segments include major products such guidance systems, needle based guns, needles, and forceps. Guidance systems have the highest market share amongst all the product. In 2015, guidance systems has 38% market share which expected to remain high till 2022.
Presently, North America and Europe holds the largest market share of the field i.e. more than 60% of the market total. Followed by Asia pacific.
Some of the major market players listed in the report are Angiotech, Boston Scientific, Cardinal Health, Carefusion Corp, etc.
SCOPE OF THE REPORT
1. Global Biopsy Devices Market By Product 2012 – 2022 ($ BILLION)
1.1. Global Needle-Based Biopsy Guns 2012 – 2022 ($ BILLION)
1.1.1. Global Vacuum-Assisted Biopsy (VAB) Devices 2012 – 2022 ($ BILLION)
1.1.2. Global Core Needle Biopsy (CNB) Devices 2012 – 2022 ($ BILLION)
1.1.3. Global Fine Needle Aspiration Biopsy (FNAB) Devices 2012 – 2022 ($ BILLION)
1.2. Global Biopsy Needles 2012 – 2022 ($ BILLION)
1.2.1. Global Disposable Biopsy Needles 2012 – 2022 ($ BILLION)
1.2.2. Global Reusable Biopsy Needles 2012 – 2022 ($ BILLION)
1.3. Global Biopsy Forceps 2012 – 2022 ($ BILLION)
1.3.1. Global Cold (General) Biopsy Forceps 2012 – 2022 ($ BILLION)
1.3.2. Global Hot Biopsy Forceps 2012 – 2022 ($ BILLION)
1.4. Global Biopsy Guidance Systems 2012 – 2022 ($ BILLION)
1.4.1. Global Manual Guidance Systems 2012 – 2022 ($ BILLION)
1.4.2. Global Robotic Guidance Systems 2012 – 2022 ($ BILLION)
1.5. Global Others 2012 – 2022 ($ BILLION)
1.5.1. Global Biopsy Brushes 2012 – 2022 ($ BILLION)
1.5.2. Global Biopsy Curettes 2012 – 2022 ($ BILLION)
1.5.3. Global Biopsy Punches 2012 – 2022 ($ BILLION)
2. Global Biopsy industry regional outlook 2012-2022 ($ billion)
2.1. North America
2.3. Asia Pacific
2.4. Middle East & Africa
2.5. Central & South America
3. Competitive Landscape
3.2. BOSTON SCIENTIFIC
3.3. CARDINAL HEALTH
3.4. CAREFUSION CORP.
3.5. COOK MEDICAL
3.6. CR BARD
3.8. DTR MEDICAL
3.10. FUJIFILMS HOLDINGS CORP.
3.12. MAUNA KEA TECHNOLOGIES
3.13. MDXHEALTH INC.
3.15. SANARUS TECHNOLOGIES
3.16. VERNA MEDICAL TECHNOLOGIES
3.17. INRAD INC.
3.18. UK BIOPSY
Release ID: 877